FDA Grants Accelerated Approval to Zenbexus (iberdomide) for Relapsed or Refractory Multiple Myeloma

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. This approval marks the introduction of a new drug class, CELMoDs (cereblon-modulating protein degraders), for multiple myeloma treatment.